Trabectedin and its potential in the treatment of soft tissue sarcoma. - Wikidata - wikimedia - TriplyDB

Trabectedin and its potential in the treatment of soft tissue sarcoma.

Trabectedin and its potential in the treatment of soft tissue sarcoma.

http://www.wikidata.org/entity/Q33380903

about

Treatment of early uterine sarcomas: disentangling adjuvant modalities Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Complete remission of a reccurrent mesenteric liposarcoma with rare histological features following the administration of trabectedin.Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.

P2860

Q21245577-E71B09FA-E7C6-4EB8-A18C-F2DE027E9BCA Q26745502-2D8C8517-0E22-44A7-A17F-9CA05D624884 Q35693620-591D9DE5-6A61-49CC-8DAD-9DC1B7FE1818 Q35898258-CD245FEF-9FFA-44A1-BB34-6C2E3AD26803 Q36273796-501D4CEB-B2DE-4476-85BB-B162738F971F Q37388663-EECC2739-0DDA-4EF1-8B9F-D0FB2873483C Q38849896-6B6358E2-A960-40F2-9283-88B946DADE93

P2860

Trabectedin and its potential in the treatment of soft tissue sarcoma.

http://www.wikidata.org/entity/Q33380903

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Trabectedin and its potential in the treatment of soft tissue sarcoma.

@ast

Trabectedin and its potential in the treatment of soft tissue sarcoma.

@en

type

label

Trabectedin and its potential in the treatment of soft tissue sarcoma.

@ast

Trabectedin and its potential in the treatment of soft tissue sarcoma.

@en

prefLabel

Trabectedin and its potential in the treatment of soft tissue sarcoma.

@ast

Trabectedin and its potential in the treatment of soft tissue sarcoma.

@en

P1433

Q33380903-0351DD65-7E10-4A8B-AE29-A1596FC7A6C9

P1476

Q33380903-33350F9E-368E-480D-8809-7445084FC8C1

P2093

Q33380903-25328F16-212A-47FB-B082-A2CCD9B5F113

Q33380903-700A4513-1AAF-4EAE-8171-44766AA822E3

Q33380903-7AD3083C-A3EF-442E-8F12-96543BF1F9C2

Q33380903-EC39C708-9669-44B1-AEA6-459FCCC106CA

P2860

Q33380903-082730B1-54E2-4DA4-A721-28D67106BABE

Q33380903-09FAB3BA-BDCB-4AFB-AF7F-F1F74E7564E1

Q33380903-0AA5693D-B139-45B9-8BDE-4E3FC4D1C5D6

Q33380903-0D2FF55E-3AB2-4BAF-B080-003911782A4B

Q33380903-1B7E228E-4D18-4C14-B24B-F46AC9A068AE

Q33380903-21D20B80-0771-48F6-A36B-41DB9C29D454

Q33380903-275152B6-16F5-48C8-AFAF-7723A7D58B03

Q33380903-2DCF6BC1-D0F0-4080-B730-E9A5CE76B177

Q33380903-33D1D49D-8734-4649-9829-8EA901797D30

Q33380903-3C0D3FEA-FE22-4375-95D1-8150127474AF

P304

Q33380903-B185815C-8497-45A6-8AD3-7EAF9F5E539B

P31

Q33380903-8b812c8e-7ad0-4673-9c22-4fc37f6394d4

Q33380903-F43B6373-E70A-4D01-AA2D-4FFCF9FFEE5A

P356

Q33380903-79DF74AF-919D-4C9F-9C28-85DDB7D518BC

P433

Q33380903-7AD59F22-CA6F-4125-870B-F216CC0864DA

P478

Q33380903-59C7F523-9E2A-45A8-B419-2BAC7BF49D06

P50

Q33380903-56C00193-A395-4952-BA69-12916A183094

P577

Q33380903-68AA73AB-4DAA-40F7-BD3F-C72514999678

P698

Q33380903-0D3DDE77-123B-4405-A1AD-0F166F4052BE

P932

Q33380903-DC3360C3-7DF9-4076-8DF1-3A2C22C62FAC

P356

P1433

Therapeutics and Clinical Risk Management

P1476

Trabectedin and its potential in the treatment of soft tissue sarcoma

@en

P2093

Armelle Dufresne

http://www.w3.org/2001/XMLSchema#string

Jean-Yves Blay

http://www.w3.org/2001/XMLSchema#string

Jérôme Fayette

http://www.w3.org/2001/XMLSchema#string

Philippe A Cassier

http://www.w3.org/2001/XMLSchema#string

P2860

Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.

P304

109-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S1174

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18728699

http://www.w3.org/2001/XMLSchema#string

P932

2503645

http://www.w3.org/2001/XMLSchema#string